- Conditions
- Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- laromustine
- Drug
- Lead sponsor
- Vion Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2008
- U.S. locations
- 3
- States / cities
- New Haven, Connecticut • West Haven, Connecticut • Cleveland, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 601–624
of 977
matching trials from the live ClinicalTrials.gov search.
- Conditions
- B-cell Acute Lymphoblastic Leukemia, B-cell Non Hodgkin Lymphoma
- Interventions
- CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 31 Days to 30 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2031
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Childhood Langerhans Cell Histiocytosis, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Interventions
- umbilical cord blood transplantation
- Procedure
- Lead sponsor
- Herbert Irving Comprehensive Cancer Center
- Other
- Eligibility
- Up to 60 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hematological Malignancy, Acute Leukemia in Remission, Acute Lymphoblastic Leukemia in Remission, Myelodysplastic Syndromes, Non-Hodgkin Lymphoma, Hodgkin Lymphoma
- Interventions
- Cord blood stem cells, Valproic Acid, Fludarabine, cytoxan, Thiotepa, TBI
- Biological · Drug
- Lead sponsor
- Alla Keyzner
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes, Cetuximab, Computed Tomography, Cyclophosphamide, Echocardiography, Fludarabine, Leukapheresis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Positron Emission Tomography
- Procedure · Biological · Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Leukemia
- Interventions
- filgrastim, asparaginase, cyclophosphamide, daunorubicin hydrochloride, dexamethasone, etoposide, leucovorin calcium, liposomal cytarabine, mercaptopurine, mesna, methotrexate, therapeutic hydrocortisone, thiotepa, vincristine sulfate, low-LET electron therapy, low-LET photon therapy
- Biological · Drug · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 20 Years
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1996
- U.S. locations
- 62
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 48 more
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Small Intestine Cancer
- Interventions
- cyclophosphamide, allogeneic bone marrow transplantation, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 50 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2002
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin
- Interventions
- JCAR017, Lymphodepleting, Fludarabine, Cyclophosphamide
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- Up to 25 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 9
- States / cities
- Duarte, California • Redwood City, California • St. Petersburg, Florida + 6 more
- Conditions
- Acute Myeloid Leukemia in Remission, Adult Acute Lymphoblastic Leukemia in Remission, Chronic Myelogenous Leukemia (CML), Non-Hodgkin's Lymphoma (NHL) or Hodgkin's Disease (HD) in 2nd or Greater Complete Remission, Partial Remission, Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Myelodysplastic Syndrome (MDS), Myeloproliferative Disorders
- Interventions
- POL6326, Leukapheresis, PBSC Transplant
- Drug · Procedure
- Lead sponsor
- Polyphor Ltd.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 2
- States / cities
- Kansas City, Kansas • St Louis, Missouri
- Conditions
- Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Myelodysplastic Syndrome
- Interventions
- VCL-CB01, Phosphate-buffered Saline (PBS)
- Biological · Other
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 22
- States / cities
- Tucson, Arizona • Duarte, California • Denver, Colorado + 17 more
- Conditions
- Non-Hodgkin's Lymphoma (disorder), Acute Lymphoid Leukemia, Disease (disorder)
- Interventions
- 1A46 Injection
- Drug
- Lead sponsor
- Chimagen Biosciences, Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 5
- States / cities
- New Haven, Connecticut • Louisville, Kentucky • Pittsburgh, Pennsylvania + 2 more
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aplastic Anemia, Bone Marrow Failure, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Follicular Lymphoma, Hodgkin Lymphoma, Mantle Cell Lymphoma, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Plasma Cell Myeloma
- Interventions
- Anti-Thymocyte Globulin, Cyclophosphamide, Cytokine-treated Veto Cells, Fludarabine, Peripheral Blood Stem Cell Transplantation, Total-Body Irradiation
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Myelodysplasia, Lymphoma, Non-Hodgkin's, Mantle-Cell Lymphoma, Hodgkin's Disease, Multiple Myeloma, Myelofibrosis
- Interventions
- Cyclophosphamide, Fludarabine, Cyclosporine, Mycophenolate mofetil, Basiliximab
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Lymphoma
- Interventions
- filgrastim, rituximab, busulfan, cisplatin, cyclophosphamide, cytarabine, doxorubicin hydrochloride, etoposide, methylprednisolone, prednisone, vincristine sulfate, autologous bone marrow transplantation, peripheral blood stem cell transplantation, positron emission tomography, fludeoxyglucose F 18, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Lung Cancer, Lymphoma, Lymphoproliferative Disorder, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- bevacizumab, vandetanib, laboratory biomarker analysis, pharmacological study
- Biological · Drug · Other
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Adult B Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia
- Interventions
- Cytarabine, Deglycosylated Ricin A Chain-Conjugated Anti-CD19/Anti-CD22 Immunotoxins, Laboratory Biomarker Analysis, Pharmacological Study
- Drug · Biological · Other
- Lead sponsor
- Albert Einstein College of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 2
- States / cities
- The Bronx, New York • Philadelphia, Pennsylvania
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma, Myelofibrosis, Anemia, Aplastic, Hemoglobinuria, Paroxysmal
- Interventions
- Basiliximab
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Lymphoproliferative Malignancies, Acute Myeloid Leukemia
- Interventions
- ZEN003365
- Drug
- Lead sponsor
- Zenith Epigenetics
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 4
- States / cities
- St Louis, Missouri • New York, New York • Springfield, Oregon + 1 more
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- aldesleukin
- Biological
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- Up to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2000
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- B Acute Lymphoblastic Leukemia
- Interventions
- Biospecimen Collection, Blinatumomab, Bone Marrow Biopsy, Calaspargase Pegol, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin, Doxorubicin, Echocardiography Test, Imatinib, Leucovorin, Mercaptopurine, Methotrexate, Multigated Acquisition Scan, Pegaspargase, Prednisolone, Prednisone, Radiation Therapy, Thioguanine, Vincristine
- Procedure · Biological · Drug + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 366 Days to 46 Years
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 143
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 121 more
- Conditions
- Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia in Remission, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome With Excess Blasts, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory Mixed Phenotype Acute Leukemia, Hematopoietic and Lymphoid Cell Neoplasm
- Interventions
- Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10, Cyclophosphamide, Total-Body Irradiation, Peripheral Blood Stem Cell Transplantation, Bone Marrow Transplantation, Mycophenolate Mofetil, Recombinant Granulocyte Colony-Stimulating Factor, Fludarabine Phosphate, Tacrolimus, Bone Marrow Aspiration and Biopsy, Biospecimen Collection
- Biological · Drug · Radiation + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Relapsed B-Cell Acute Lymphoblastic Leukemia
- Interventions
- leukapheresis or collection of PBMCs, cyclophosphamide based chemotherapy regimens, modified T cells
- Procedure · Drug · Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Up to 26 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2027
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • New York, New York
- Conditions
- Hairy Cell Leukemia (HCL), Chronic Lymphocytic Leukemia (CLL), Non-Hodgkins Lymphoma (NHL), Cutaneous T Cell Lymphoma (CTCL), Adult T Cell Lymphoma (ATL)
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 1,263 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2010
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Lymphoblastic Leukemia
- Interventions
- Dasatinib
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2040
- U.S. locations
- 1
- States / cities
- Palo Alto, California